Please login to the form below

Not currently logged in
Email:
Password:

Pfizer tries to quash Trovan report in Nigeria

Pfizer initiates legal action in Nigerian Federal high court to quash a report by the Investigating Committee on Trovan

Pfizer has initiated a legal action in the Abuja division of the Nigerian Federal high court to quash a report by the Investigating Committee on the Trovan (trovafloxacin) clinical trial conducted in Kano state in 1996.

The government had charged Pfizer and eight others with alleged criminal application of trovafloxacin on 200 Nigerian children. The trial, it is alleged, killed many of the children and left others with various permanent disabilities.

The new Pfizer suit has demanded an order of certiorari (a type of writ seeking judicial review) and the action was assigned to Justice Anwuri Chikere for trial.

If successful, the certiorari could nullify the multiple criminal and civil actions against Pfizer Nigeria and individuals Isa Dutse, Scott Hopkins, Debra Williams, Mike Dunne, Samuel Ohuabunwa, Robert Buhl and William Steere, all of whom face a total 23-count charge.

The high court judge had granted Pfizer an extension of time to apply for leave to challenge the report. The accused could not be arraigned as they were not in court at the last adjourned date.

31st July 2007

Share

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

Actinic keratosis – a common skin condition that can lead to skin cancer
PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
Man vs microbe: the fight against antimicrobial resistance
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...